<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="4349"><DrugName>SC-41930</DrugName><DrugSynonyms><Name><Value>CGS-24115</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>SC-41930</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>120072-59-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18362">GD Searle &amp; Co</CompanyOriginator><CompaniesSecondary><Company id="18362">GD Searle &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="4349" type="Drug"><TargetEntity id="147403" type="siDrug">SC-41930</TargetEntity></SourceEntity><SourceEntity id="18362" type="Company"><TargetEntity id="5001166864" type="organizationId">GD Searle &amp; Co</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="189" type="ciIndication"><TargetEntity id="10021972" type="MEDDRA"></TargetEntity><TargetEntity id="D015212" type="MeSH"></TargetEntity><TargetEntity id="-156308446" type="omicsDisease"></TargetEntity><TargetEntity id="394" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="3166" type="Action"><TargetEntity id="238" type="Mechanism">Leukotriene BLT (LTB4) Antagonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication><Indication id="189">Inflammatory bowel disease</Indication><Indication id="281">Psoriasis</Indication></IndicationsSecondary><ActionsPrimary><Action id="3166">Leukotriene BLT receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="15184">Systemic antipsoriatic product</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-01T05:32:26.000Z</LastModificationDate><ChangeDateLast>2003-04-17T11:12:02.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18362" linkType="Company"&gt;Searle&lt;/ulink&gt; has discontinued development of &lt;ulink linkID="4349" linkType="Drug"&gt;SC-41930&lt;/ulink&gt;, an LTB4 antagonist which had reached phase II clinical trials for the potential treatment of inflammatory bowel disease (ulcerative colitis). It also had potential for the treatment of other inflammatory conditions such as psoriasis. &lt;/para&gt;&lt;para&gt;The racemate (SC-50605) and (+)-enantiomer of the racemate (&lt;ulink linkID="4359" linkType="Drug"&gt;SC-52798&lt;/ulink&gt;) are both in preclinical development and are the back up compounds for &lt;ulink linkID="4349" linkType="Drug"&gt;SC-41930&lt;/ulink&gt;, which is less potent and less selective by comparison [&lt;ulink linkID="174757" linkType="reference"&gt;174757&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="281">Psoriasis</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="189">Inflammatory bowel disease</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="188">Inflammatory disease</Indication></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="281">Psoriasis</Indication><Source id="174757" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><Source id="174757" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><Source id="174757" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01229"><Name>Leukotriene BLT receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CCCc1c(ccc2c1OC(CC2)C(=O)O)OCCCOc3ccc(c(c3CCC)OC)C(=O)C</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="129298" number="WO-00012086" title="Method of mitigating the adverse effects of interleukin-2"/><PatentFamily id="1983120" number="EP-00292977" title="Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives."/><PatentFamily id="801877" number="WO-2004108077" title="Method of mitigating the adverse effects of il-2"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Intarcia Therapeutics Inc" id="27264"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>